Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY ASSESSING THE LONG-TERM EFFECT OF DUPILUMAB ON PREVENTION OF LUNG FUNCTION DECLINE IN PATIENTS WITH UNCONTROLLED MODERATE TO SEVERE ASTHMA

Intervention/treatment:
DUPILUMAB (SAR231893/REGN668)
Medical condition:
ASTHMA
Protocol code:
LPS16676
Control number:
256573
Status:
Active, not recruiting
Approved:
October 13, 2021
Trial phase:
Phase 4
For more information:
ClinicalTrials.gov - NCT05097287
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial Transparency email recommended (Toll free number for US & Canada)
Role
CONTACT
Phone:
800-633-1610
Extension option 6
Sponsor
SANOFI AVENTIS

Locations

Alberta

Investigational Site Number : 1240028
Calgary, Alberta, T3B 0M3
COMPLETED

British Columbia

Investigational Site Number : 1240004
Vancouver, British Columbia, V6Z 1Y6
COMPLETED
Investigational Site Number : 1240020
Kelowna, British Columbia, V1W 3H5
COMPLETED
Investigational Site Number : 1240022
Vancouver, British Columbia, V5Z 1M9
ACTIVE_NOT_RECRUITING

New Brunswick

Investigational Site Number : 1240010
Moncton, New Brunswick, E1G 5C4
COMPLETED

Ontario

Investigational Site Number : 1240001
Toronto, Ontario, M5T 3A9
ACTIVE_NOT_RECRUITING
Investigational Site Number : 1240003
Windsor, Ontario, N8X 5A6
COMPLETED
Investigational Site Number : 1240007
Toronto, Ontario, M9V 4B4
ACTIVE_NOT_RECRUITING
Investigational Site Number : 1240011
Toronto, Ontario, M5G 1E2
ACTIVE_NOT_RECRUITING
Investigational Site Number : 1240015
Ajax, Ontario, L1S 2J5
ACTIVE_NOT_RECRUITING
Investigational Site Number : 1240018
Niagara Falls, Ontario, L2H 1H5
COMPLETED
Investigational Site Number : 1240029
Kingston, Ontario, K7M 7E4
COMPLETED

Quebec

Investigational Site Number : 1240002
Québec, Quebec, G1G 3Y8
ACTIVE_NOT_RECRUITING
Investigational Site Number : 1240014
Montreal, Quebec, H1Y 3H5
COMPLETED
Investigational Site Number : 1240017
Montreal, Quebec, H3T 1E2
ACTIVE_NOT_RECRUITING
Investigational Site Number : 1240023
Montreal, Quebec, H4A 3J1
COMPLETED
Investigational Site Number : 1240025
Sherbrooke, Quebec, J1H 5N4
ACTIVE_NOT_RECRUITING

Saskatchewan

Investigational Site Number : 1240024
Saskatoon, Saskatchewan, S7N 0W8
COMPLETED
Did you find what you were looking for?